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Chardack and MacCallum2 reported the case of a
patient who survived long term after surgical resection
and postoperative radiation. Subsequently, Shaw,3
Paulson,4 and their associates found that preoperative
radiation facilitated surgical resection and that this
combined treatment was potentially curative. On the
basis of their experience, preoperative radiation fol-
lowed by surgical resection has been a standard of care
for lung cancers of the superior sulcus for the past 25
years.
Although many small surgical series attest to the fea-
sibility of this treatment regimen (Table I), survival at 5
years remains approximately 25% to 30%. The recent
success of combined modality therapy, especially
induction chemotherapy, in the management of stage
IIIA (N2) NSCLC has stimulated interest in applying
this approach to lung cancers of the superior sulcus. As
a result, the treatment of lung cancers of the superior
sulcus is now in flux, with various combinations of
N on–small cell carcinoma of the lung (NSCLC)involving the superior sulcus was first described by
Henry Pancoast1 in 1932. This uncommon form of
NSCLC was considered incurable until 1956, when
Background: The treatment of superior sulcus lung cancers is evolving and
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benchmark against which new therapies can be assessed, we reviewed our
24-year experience with patients undergoing thoracotomy for lung cancers
of the superior sulcus. 
Methods: Data were acquired through retrospective chart review. Overall
survival was calculated by the method of Kaplan and Meier, and prognostic
factors were examined by log rank and Cox proportional hazards modeling. 
Results: From 1974 to 1998, 225 patients underwent thoracotomy. The
patients included 144 men (64%) and 81 women with a median age of 55
years. The majority of patients (55%) received preoperative radiation, but
35% did not have any preoperative treatment. Tumor stages were IIB (T3
N0) in 52%, IIIA in 15%, and IIIB in 27% of patients. Complete resection
was achieved in 64% of T3 N0 tumors, 54% of T3 N2 tumors, and 39% of
T4 N0 tumors. Operative mortality was 4%. Median survival was 33 months
for stage IIB and 12 months for both stages IIIA and IIIB. Actuarial 5-year
survivals were 46% for stage IIB, 0% for stage IIIA, and 13% for stage IIIB.
By univariate and multivariable analyses, T and N status and complete resec-
tion had a significant impact on survival. Locoregional disease was the most
common form of relapse. 
Conclusions: Our results provide a benchmark against which new treatment
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chemotherapy and radiation often being given in the
preoperative period in a highly individualized manner.
A prospective multi-institutional phase II trial
(Intergroup trial 0160, SWOG trial 9416) is currently
underway to test the use of concurrent induction
chemotherapy and radiation followed by surgical resec-
tion in both T3 and T4 N0-1 lung cancers of the supe-
rior sulcus. It is important to have a large and reliable
historical experience against which to assess the valid-
ity of this new regimen.
Our previous analysis, based on 124 patients,5
focused on the use of brachytherapy and found that this
did not improve local control or survival. Instead, com-
pleteness and type of resection and nodal metastases
seemed to be significant prognostic factors. These
results prompted us to focus on careful preoperative
staging and extended resections that might improve
long-term outcome. The current series extends our pre-
vious experience and allows a more definitive analysis
of factors affecting local control and survival, as well as
sites of relapse, in patients undergoing surgery for both
T3 and T4 lung cancers of the superior sulcus.
Patients and methods
Patients with NSCLC involving the apex of the lung and chest
wall, associated with pain radiating down the arm with or with-
out additional neurologic symptoms (eg, Horner syndrome),
were identified from the institutional and thoracic service data-
bases. The previously reported 124 cases were included, there-
by providing for analysis a large experience spanning 24 years.
Only patients treated by thoracotomy were analyzed.
A detailed retrospective chart review was performed and
the following items were recorded: patient age and sex; his-
tologic tumor type and TNM status; type of preoperative and
postoperative treatment; type of operation; whether resection
was complete; disease status at last follow-up contact; and,
when appropriate, date and sites of relapse. A resection was
considered complete if the surgeon recorded that all gross
tumor was removed and the surgical margins were histologi-
cally free of disease (negative). When not available by chart
review, follow-up information was obtained by direct com-
munication with the patient, family, or referring physician.
Statistical analyses were performed with SAS and S Plus
software (SAS Institute, Inc, Cary, NC). Survival probabilities
were calculated by the product limit method of Kaplan and
Meier.6 The prognostic significance of factors was tested in a
univariate model by log rank statistic for categorical covariates
and by proportional hazards regression for continuous covari-
ates. Proportional hazards regression was used to test the prog-
nostic significance of factors in a multivariable model.6-8
Results
From January 1974 through January 1998, 225
patients underwent thoracotomy for possible resection
of an NSCLC of the superior sulcus. The demographic
features and data about the type of preoperative treat-
ment and operation performed are shown in Table II.
The majority of patients were male, and there was a
preponderance of nonsquamous tumors. Approxi-
mately two thirds of the patients received some form of
preoperative therapy, most frequently radiation, in
keeping with the traditional approach to the manage-
ment of lung cancers of the superior sulcus. The medi-
an dose of preoperative radiation was 4248 cGy (range
400-8000 cGy). The use of induction chemotherapy in
20% of patients reflects empiric extension of a now
accepted treatment of stage IIIA (N2) NSCLC to the
management of lung cancers of the superior sulcus.
The lack of preoperative treatment in 35% of patients
reflects individual surgeon choice to attempt a wide
resection followed by high-dose external-beam radia-
tion after the operation.
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Table I. Results of series reporting outcome after surgery for lung cancers of the superior sulcus
First author No. of Preoperative Percent having Two-year Five-year
(year) patients treatment complete resection survival survival
Paulson4 (1975) 61 RT NS 34% 26%
Miller10 (1978) 26 RT NS NS 32%
Attar11 (1979) 73 RT 48% 23% (3 y) NS
Stanford12 (1980) 16 RT NS NS 49%
Anderson14 (1986) 28 RT 50% NS 34%
Devine13 (1986) 40 RT 70% NS 10%
Shahian16 (1987) 18 RT 50% 64% 56%
Wright15 (1987) 21 RT NS 55% 27%
Sartori20 (1992) 42 RT NS 38% 25%
Dartevelle25 (1993) 29 None (postop RT) NS 50% 31%
Ginsberg5 (1994) 124 RT 56% 45% 26%
Maggi22 (1994) 60 RT 60% NS 17.4%
Martínez-Monge24 (1994) 18 Chemo + RT 76% NS 56% (4 y)
Muscolino21 (1997) 15 RT 73% NS 26.6%
RT, Radiation; Chemo, chemotherapy; NS, not stated.
The most frequent operation performed was a lobec-
tomy, usually in conjunction with a chest wall resection
(Table II). The use of a limited resection, either a
wedge resection or segmentectomy, has been largely
abandoned in light of our previous experience,5 which
suggested that overall suravival was lower with limited
resection than with lobectomy (Table III). The minori-
ty of patients who did not have a chest wall resection
performed are those who had such a significant tumor
regression with induction treatment that chest wall
resection no longer seemed warranted at thoracotomy.
The overall operative mortality for all patients who
underwent thoracotomy was 4%.
The final tumor TNM status and the number of
patients in each tumor stage who had a complete resec-
tion and information about survival by stage are shown
in Table IV. Among the 55 patients with T4 tumors, the
most common site of T4 disease was the spine, which
was affected in 34 (62%) of those patients. The inclu-
sion of patients in this series who had N2 disease
reflects an era at our institution during the 1970s and
early 1980s when mediastinoscopy was not routinely
performed. Not surprisingly, our results indicate that a
complete resection was more likely to be feasible in
earlier stage tumors, being more frequent among T3 N0
tumors than among T3 N2 or T4 N0 tumors. The rate
of complete resection for T3 N0 tumors was higher in
our most recent experience (73%) than it was for the
first 124 cases reported (53%). This may reflect
changes in patient selection and surgical technique.
The median length of follow-up was 2 years (range
0-20 years). Information about overall survival and the
relationship between this and several prognostic factors
is shown in Figs 1 to 3. By univariate analyses, patients
with stage IIB tumors (Fig 1) had a significantly better
survival than those with stage IIIA or IIIB tumors (P <
.01). There was no significant difference in survival
between stages IIIA and IIIB (P = .7). When the 3
largest groups of patients were compared, namely T3
N0 versus T3 N2 and T4 N0, the patients with T3 N0
tumors had a significantly better survival than the other
2 groups (P < .001). There was no significant differ-
ence in survival between patients with T3 N2 tumors
and those with T4 N0 tumors (P = .8).
Additional univariate analyses indicated that com-
plete resection (Fig 2) and N0 nodal status (Fig 3) also
had a significant impact on overall survival. However,
neither preoperative nor postoperative treatment had a
significant impact on survival (P = .06 for preoperative
and P = .8 for postoperative treatment).
Potential prognostic factors were then also examined
in a multivariable analysis (Table V). These included
patient age and sex, T and N status, the type of resec-
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Table II.  Demographic features and treatment 
information about the 225 patients with NSCLC 
of the superior sulcus who underwent thoracotomy












Large cell 25 (13%)
Preoperative treatment 
(No. of patients, % total)
Radiation only 101 (45%)
Chemotherapy only 23 (10%)
Chemotherapy + radiation 22 (10%)
None 78 (35%)
Type of operation 
(No. of patients, % total) 
Thoracotomy, no resection 31 (14%)
Wedge/segmentectomy only 29
+ Chest wall resection 39 83 (31%)
+ Chest wall + spine resection 15
Lobectomy only 9
+ Chest wall resection 65
+ Chest wall + spine resection 28
107 (47%)
+ Chest wall + subclavian vessels 5
Pneumonectomy only 1
4 (2%)+ Chest wall resection 3
*Twenty-eight patients had NSCLC, not otherwise. specified.
Table III.  Types of pulmonary resection, rates of
complete resection, and sites of first recurrence in 
the current series compared with our previous series
Previous series Current series
N = 124 N = 101
(1974-1991) (1992-1998)
Type of resection
Thoracotomy only 24 (19%) 7 (7%)
Wedge/segmentectomy 69 (56%) 14 (14%)
Lobectomy 31 (25%) 76 (75%)
Pneumonectomy 0 4 (4%)
No. of patients with complete resection
T3 54/101 (53%) 46/63 (73%)
T4 15/23 (65%) 5/32 (15%)
Sites of first recurrence
Locoregional 45 (36%) 32 (31.5%)
Distant 21 (17%) 25 (25%)
Locoregional + distant 0 4 (4%)




tion performed, the type of preoperative therapy, the
histologic tumor type, and the completeness of resec-
tion. Only the completeness of resection and the T and
N status still had a significant impact on overall sur-
vival. 
Locoregional recurrence was the most common site
of first relapse, occurring in 40% of patients (Table III).
Information about the precise sites of locoregional
relapse was available in 154 patients and is shown in
Table VI. The most frequent sites were the spine, chest
wall, and lung. Among patients with T4 tumors, half of
all recurrences involved the spine.
Discussion
The management of NSCLC of the superior sulcus
has evolved significantly during the past 4 decades.
The early reports by Shaw,3,9 Paulson,4 Miller,10
Attar,11 and their associates focused on the feasibility
of preoperative radiation and surgical resection and on
the fact that lung cancers of the superior sulcus were
not universally fatal, as assumed previously.
During the 1980s, several reports12-19 established the
“Paulson regimen” of preoperative radiation followed
by surgical resection as a standard of care that led to an
approximate 30% survival at 5 years (Table I). From
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Table IV.  Information about stage, resectability, and survival among the 225 patients who underwent thoracotomy
for lung cancers of the superior sulcus
No. of No. of complete Median survival Two-year survival Five-year
Stage TNM patients (% total) resections (%) (mo) (95% CI) (95% CI) survival (95% CI)
0 T0 N0 M0 6 6 * * *
IIB T3 N0 M0 117 (52) 75 (64) 33 (24, 84) 59% (50, 69) 46% (36, 57)
IIIA (n = 33) T3 N1 M0 9 7 12 (8, 20) 29% (16, 53) 0% (N/A)
T3 N2 M0 24 (10) 13 (54)
IIIB (n = 61) T3 N3 M0 7 1 12 (8, 17) 33% (22, 49) 13% (6, 30)
T4 NX M0 2 0
T4 N0 M0 45 (20) 17 (38)
T4 N1 M0 6 2
T4 N2 M0 1 0
IV† (n = 8) T3 N0 M1 4 2 * * *
T3 N1 M1 1 1
T3 N2 M1 2 1
T4 N2 M1 1 1
The 95% confidence intervals (CI) are noted in parentheses under the median, 2-year, and 5-year survival figures.
*Number too small to calculate survival.
†M1, Solitary site, resected.
Fig 1.  Survival curve estimates stratified by stage (IIB, IIIA, IIIB, IV).
this experience it appeared that N2 disease, diseased
(positive) margins, and vertebral body involvement
might have an adverse impact on overall sur-
vival.4,14,20,21 However, the significance of these prog-
nostic factors was not firmly established because pub-
lished reports usually described small numbers of
patients treated in variable ways over many years. Not
all authors agreed on the poor prognostic impact of T4
disease so long as complete resection was achieved.15
On the other hand, there has been a growing recogni-
tion of the importance of mediastinoscopy and the fact
that N2 disease, as for all other subsets of stage III
NSCLC, was associated with the early development of
distant metastases and an extremely poor survival.4,14,15
During the 1990s, reports have focused on defining
prognostic factors,5,20-22 on determining the role of
brachytherapy,5 and on exploring new techniques that
facilitate complete resection of T4 tumors.18,23 Our pre-
vious analysis, based on 124 patients operated on from
1974 to 1991, showed that brachytherapy did not con-
tribute significantly to local control and suggested that
N2 disease, completeness of resection, T4 tumors, and,
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Fig 2.  Survival curve estimates stratified by complete resection.
Fig 3.  Survival curve estimates stratified by nodal status (N0, N1-2).
to a lesser degree, limited pulmonary resection had an
adverse impact on survival. Since then, medi-
astinoscopy, with or without scalene node biopsy, has
been a routine part of our preresection evaluation of
superior sulcus tumors. The neurosurgeons and ortho-
pedic surgeons frequently participate in preoperative
evaluation and surgical resection. Formal vertebral
resection is performed whenever indicated to try to
ensure complete resection of tumor abutting or involv-
ing the spine. Although common patterns of tumor
invasion of the spine sometimes preclude en bloc resec-
tion, negative surgical margins can usually be obtained,
at least for T3 tumors. However, our recent experience
indicates that a complete resection is still not achieved
for many T4 tumors.
Most recently, interest in exploring the potential ben-
efit of preoperative chemotherapy has been increasing.
The small series of 18 cases reported by Martínez-
Monge and associates24 suggests that induction
chemoradiotherapy may improve the likelihood of
pathologic complete response, local control, and over-
all survival. This approach to treatment is now being
formally tested in a prospective multi-institutional clin-
ical trial. Our current series, which includes almost
twice the number of cases we reported previously, pro-
vides an important benchmark against which to assess
the value of a new approach to treatment, because most
of our patients had a surgical resection with preopera-
tive and/or postoperative radiation with no consistent
use of chemotherapy. Our current experience highlights
several important aspects of the management of superi-
or sulcus tumors. In addition to emphasizing the impact
of T and N status on overall survival, it clearly demon-
strates the importance of complete resection and the
fact that only approximately half of all tumors are
amenable to complete resection when managed in the
traditional manner. Although the rates of complete
resectability and 5-year survival are better for T3 N0
tumors (64% and 46%, respectively) than for the other
TN subsets, they are still unacceptably low. This prob-
lem is not usually emphasized, but a review of pub-
lished series (Table I) indicates that our rate of incom-
plete resection is similar to that reported by other
authors. Locoregional recurrence remains the predom-
inant form of relapse for both T3 and T4 tumors,
although this is obviously a greater problem for T4
tumors involving the spine. Future efforts to improve
the results will entail not only a multidisciplinary
approach to en bloc extended resection of adjacent
structures, most frequently the spine, but also preoper-
ative therapy that yields greater tumor regression,
thereby improving the rates of complete resection that
are so critical to long-term survival in this form of
NSCLC.
Some of the patients in this series were operated on by Drs
Nael Martini and Patricia McCormack (both retired) and by
the late Dr Michael Burt. We thank Melody Owens for her
expert assistance in manuscript preparation.
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